Evidence map›Paper›PMID 41102082›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2025

Corrigendum to "Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)": [Ann Oncol 26 (2015) 2168-2173].

E Bompas, A Le Cesne, E Tresch-Bruneel, L Lebellec, V Laurence, O Collard, E Saada-Bouzid, N Isambert, J Y Blay, E Y Amela and 6 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

E BompasDepartment of Medical Oncology, Centre René Gauducheau, Nantes, France.
A Le CesneDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
E Tresch-BruneelMethodology and Biostatistics Unit, France.
L LebellecDepartment of General Oncology, Centre Oscar Lambret, Lille, France.
V LaurenceDepartment of Medical Oncology, Institut Curie, Paris, France.
O CollardDepartment of Medical Oncology, Institut de Cancérologie de la Loire, Lucien Neuwirth, Saint Priest en Jarez, France.
E Saada-BouzidDepartment of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
N IsambertDepartment of Medical Oncology, Centre GF Leclerc, Dijon, France.
J Y BlayDepartment of Medical Oncology, Centre Léon Bérard, Lyon, France.
E Y AmelaDepartment of General Oncology, Centre Oscar Lambret, Lille, France.
S SalasDepartment of Medical Oncology, Hopital La Timone, Marseille, France.
C ChevreauDepartment of Medical Oncology, Institut Claudius Regaud, Toulouse, France.
F BertucciDepartment of Medical Oncology, Institut Paoli Calmette, Marseille, France.
A ItalianoDepartment of Medical Oncology, Institut Bergonié, Bordeaux, France.
S ClisantClinical Research Unit, Centre Oscar Lambret, Lille, France.
N PenelDepartment of General Oncology, Centre Oscar Lambret, Lille, France; Clinical Research and Methodology Platform, SIRIC OncoLille Consortium, Lille, France. Electronic address: n-penel@o-lambret.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41102082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.